Sustained improvements in disease activity score 28 (DAS28) and patient (PT)-reported outcomes (PRO) with abatacept (ABA) in rheumatoid arthritis (RA) pts with an inadequate response to anti-TNF therapy: The long-term extension (LTE) of the attain trial

被引：0
|
作者：
Sibilia, J.
Schiff, M.
Genovese, M. C.
Becker, J. P.
Li, T.
McCann, T.
Dougados, M.
机构：
[1] Univ Louis Pasteur Strasbourg 1, Ctr Hosp, Dept Rheumatol, Immunopathol Lab, Strasbourg, 94304, France
[2] Denver Arthritis Clin, Clin Res Unit, Denver, CO USA
[3] Stanford Univ, Dept Rheumatol, Palo Alto, CA USA
[4] Bristol Myers Squibb Co, Princeton, NJ USA
[5] Univ Paris 05, Hop Cochin, Dept Rheumatol, Paris, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：501 / 501
页数：1
相关论文
共 10 条
  • [1] Sustained efficacy along with improvements in disease activity score 28 (DAS 28) and patient (Pt)-reported outcomes (PROs) with abatacept (Aba) in rheumatoid arthritis (RA) pts with an inadequate response to anti-tumor necrosis factor (TNF) therapy: The long-term extension (LTE) of the attain trial
    Dougados, M.
    Schiff, M.
    Luggen, M.
    Becker, J. C.
    Aranda, R.
    Li, T.
    McCann, T.
    Schmidely, N.
    LeBars, M.
    Sibilia, J.
    Genovese, M. C.
    RHEUMATOLOGY, 2007, 46 : I99 - I99
  • [2] Abatacept provides significant and clinically meaningful efficacy in rheumatoid arthritis patients with inadequate responses to anti-TNF therapy: Disease activity score 28 assessments in the attain trial
    Dougados, M
    Sherrer, Y
    Russell, A
    Carrabba, M
    Nuamah, I
    Becker, J
    Aranda, R
    Luggen, M
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 458 - 458
  • [3] Abatacept (Aba) provides long-term efficacy and significant sustained benefits in clinical and patient (Pt)-reported outcomes (PROs) through 2 yrs in rheumatoid arthritis (RA) pts with an inadequate response to Methotrexate (MTX): The long-term extension (LTE) of the aim BA in inadequate responders to MTX) trial
    Emery, P.
    Russell, A.
    Becker, J. C.
    Aranda, R.
    Li, T.
    Teng, J.
    Schmidely, N.
    LeBars, M.
    Moreland, L. W.
    Westhovens, R.
    Kremer, J. M.
    RHEUMATOLOGY, 2007, 46 : I40 - I40
  • [4] Abatacept provides significant and sustained benefits in clinical and patient reported outcomes through 2 yrs in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX): The long-term extension (LTE) of the aim trial
    Kremer, J. M.
    Emery, P.
    Becker, J. P.
    Aranda, R.
    Teng, J.
    Li, T.
    Westhovens, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 327 - 327
  • [5] DAS28 remission and clinical efficacy in rheumatoid arthritis patients with inadequate responses to methotrexate treated with abatacept: The Phase III AIM trial and a Phase IIB trial long-term extension
    Westhovens, R
    Kremer, J
    Shergy, W
    Abud-Mendoza, C
    Aranda, R
    Becker, JC
    Zhou, Y
    Mokliatchouk, O
    Dougados, M
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S142 - S142
  • [6] Abatacept (ABA) slows radiographic progression over 2 yrs in rheumatoid arthritis (RA) patients (Pts) with an inadequate response to methotrexate (MTX): Results from the long-term extension (LTE) of the AIM trial
    Westhovens, R.
    Peterfy, C.
    Vratsanos, G.
    Becker, J. C.
    Aranda, R.
    Teng, J.
    Kremer, J.
    Genant, H. K.
    RHEUMATOLOGY, 2007, 46 : I15 - I16
  • [7] Sustained clinical efficacy demonstrated over 18 months by the selective co-stimulation modulator abatacept in Rheumatoid Arthritis (RA) patients with an inadequate response to anti-Tumour Necrosis Factor (TNF)-α therapy:: The ATTAIN (Abatacept Trial in Treatment of Anti-TNF Inadequate Responders) Trial
    Dougados, M.
    Luggen, M.
    Schiff, M.
    Sherrer, Y.
    Aranda, R.
    Covucci, A.
    Genovese, M.
    RHEUMATOLOGY, 2006, 45 : I11 - I12
  • [8] Using the derived 28-joint disease activity score patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis
    Huai Leng Pisaniello
    Samuel L. Whittle
    Susan Lester
    Fiona Menz
    Robert Metcalf
    Leah McWilliams
    Catherine L. Hill
    Susanna Proudman
    BMC Rheumatology, 6
  • [9] Using the derived 28-joint disease activity score patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis
    Pisaniello, Huai Leng
    Whittle, Samuel L.
    Lester, Susan
    Menz, Fiona
    Metcalf, Robert
    McWilliams, Leah
    Hill, Catherine L.
    Proudman, Susanna
    BMC RHEUMATOLOGY, 2022, 6 (01)
  • [10] CLINICAL OUTCOMES UP TO WEEK (W) 48 IN THE ONGOING FILGOTINIB (FIL) LONG-TERM EXTENSION (LTE) TRIAL OF RHEUMATOID ARTHRITIS (RA) PATIENTS (PTS) WITH INADEQUATE RESPONSE (IR) TO METHOTREXATE (MTX) INITIALLY TREATED WITH FIL OR ADALIMUMAB (ADA) DURING THE PHASE 3 PARENT STUDY (PS)
    Combe, B.
    Tanaka, Y.
    Emery, P.
    Pechonkina, A.
    Kuo, A.
    Gong, Q.
    Van Beneden, K.
    Rajendran, V.
    Schulze-Koops, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 615 - 616
1